Arrowhead Pharmaceuticals, Inc. (ARWR) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2024 (Fiscal Q3 2024). Arrowhead Pharmaceuticals is a biopharmaceutical company developing RNA interference (RNAi) therapeutics to treat intractable diseases. The company operates research facilities in California and Wisconsin and maintains a pipeline across cardiometabolic, pulmonary, liver, muscle, and CNS therapeutic areas.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $15.8 million | $3.6 million | $224.6 million |
| Net Loss (Attributable to ARWR) | $(170.8) million | $(102.9) million | $(429.0) million | $(95.6) million |
| Diluted EPS | $(1.38) | $(0.96) | $(3.63) | $(0.90) |
| Operating Expenses | $176.1 million | $118.5 million | $442.4 million | $321.3 million |
| Cash & Equivalents | $69.4 million (as of June 30, 2024) Available-for-sale securities: $367.3 million |
|||
| Total Assets | ||||
| Long-Term Debt/Liabilities | $336.0 million (Liability related to sale of future royalties) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to zero for Q3 2024 and to $3.6 million YTD 2024, compared to $15.8 million and $224.6 million in the prior year periods. This is due to the completion of performance obligations under major collaboration agreements (Takeda, Horizon/Amgen) in the prior year.
- Increased R&D Spend: Research and development expenses increased 61% quarter-over-quarter to $152.4 million and 46% YTD to $370.0 million. This reflects the progression of the pipeline into later-stage clinical trials, increased candidate costs, and facility expansion.
- Financing Activity: In January 2024, the company completed an underwritten offering of 15.79 million shares, raising net proceeds of $429.3 million. Additionally, a $50.0 million milestone payment was received from Royalty Pharma in Q3 2024 upon the completion of enrollment in the OCEAN(a) trial for olpasiran.
- Capital Expenditures: Significant investment in facilities continued, with $117.2 million in purchases of property and equipment YTD 2024, including the completion of a laboratory and office facility in Verona, Wisconsin.
Outlook, Risks, and Unusual Items
- Subsequent Financing: On August 7, 2024, the company entered into a senior secured term loan facility of up to $935.3 million (initial draw of $400.0 million) with Sixth Street Lending Partners. The facility bears interest at 15.0% and matures in 2031.
- Liquidity: Management expects current cash and investment resources to fund operations for at least the next twelve months.
- Pipeline Progress: Key developments include advancing plozasiran into a Phase 3 cardiovascular outcomes trial (CAPITAN), successful Phase 3 results for plozasiran in familial chylomicronemia syndrome, and new data for obesity candidate ARO-INHBE.
- Risks: The company remains pre-revenue from product sales and relies on milestone payments and equity/debt financing. Risks include the uncertainty of clinical trial outcomes, regulatory approvals, and the ability to secure future funding.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $325.6 million cash used in operating activities over the last nine months against the current cash balance of $69.4 million plus $367.3 million in securities.
- Debt Covenants: Review the terms of the new $935.3 million credit facility, specifically the 15% interest rate and restrictions on asset sales or licensing transactions.
- Revenue Recognition: Confirm the timeline for future milestone payments from partners (Amgen, GSK, Takeda) given the current lack of revenue.
- Capital Expenditure Completion: Monitor the completion of the Verona, Wisconsin facility and the associated depreciation impact on future earnings.
- Clinical Milestones: Track the enrollment and readout dates for the CAPITAN trial (plozasiran) and the OCEAN(a) trial (olpasiran) as these trigger significant cash inflows.